Powder: -20°C for 3 years | In solvent: -80°C for 1 year
VER-246608 是ATP 竞争性的丙酮酸脱氢酶激酶抑制剂,对PDK-1,PDK-3,PDK-2,和PDK-4的IC50分别为 35 nM,40 nM,84 nM 和 91 nM。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 493 | 现货 | ||
2 mg | ¥ 716 | 现货 | ||
5 mg | ¥ 1,150 | 现货 | ||
10 mg | ¥ 1,820 | 现货 | ||
25 mg | ¥ 3,490 | 现货 | ||
50 mg | ¥ 4,970 | 现货 | ||
100 mg | ¥ 7,230 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 1,410 | 现货 |
产品描述 | VER-246608 is an effective and ATP-competitive inhibitor of pyruvate dehydrogenase kinase (IC50s: 35 nM, 40 nM, 84 nM, and 91 nM for PDK-1, PDK-3, PDK-2, and PDK-4, respectively).VER-246608 disrupts Warburg metabolism and induces context-dependent cytostasis in cancer cells. Consistent with a PDK mediated MOA, VER-246608 increased pyruvate dehydrogenase complex (PDC) activity, oxygen consumption and attenuated glycolytic activity. VER-246608 was found to potentiate the activity of doxorubicin. |
靶点活性 | PDK3:40 nM, PDK1:35 nM, PDK2:84 nM, PDK4:91 nM |
体外活性 | A novel and selective ATP competitive pan-isoform inhibitor of PDK, VER-246608.?Consistent with a PDK mediated MOA, VER-246608 increased pyruvate dehydrogenase complex (PDC) activity, oxygen consumption and attenuated glycolytic activity.?However, these effects were only observed under D-glucose-depleted conditions and required almost complete ablation of PDC E1α subunit phosphorylation.?VER-246608 was weakly anti-proliferative to cancer cells in standard culture media |
分子量 | 552.96 |
分子式 | C28H23ClF2N4O4 |
CAS No. | 1684386-71-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (90.42 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.8084 mL | 9.0422 mL | 18.0845 mL | 45.2112 mL |
5 mM | 0.3617 mL | 1.8084 mL | 3.6169 mL | 9.0422 mL | |
10 mM | 0.1808 mL | 0.9042 mL | 1.8084 mL | 4.5211 mL | |
20 mM | 0.0904 mL | 0.4521 mL | 0.9042 mL | 2.2606 mL | |
50 mM | 0.0362 mL | 0.1808 mL | 0.3617 mL | 0.9042 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
VER-246608 1684386-71-7 Metabolism PI3K/Akt/mTOR signaling PDK Dehydrogenase Inhibitor PDHK VER246608 Pyruvate dehydrogenase kinase inhibit PDH kinase VER 246608 inhibitor